Pfizer Inc. $PFE Holdings Boosted by Epoch Investment Partners Inc.

Key Points

• Epoch Investment Partners Inc. increased its stake in Pfizer by 2.9%, acquiring an additional 59,811 shares, bringing their total holdings to 2,128,420 shares valued at approximately $53.93 million.
• Pfizer reported a 10.3% year-over-year revenue growth, with quarterly earnings of $0.78 per share, exceeding analysts' expectations of $0.58 per share.
• The company announced a quarterly dividend of $0.43 per share, equating to an annual yield of 6.9%, with a payout ratio currently at 91.49%.

Epoch Investment Partners Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,128,420 shares of the biopharmaceutical company's stock after purchasing an additional 59,811 shares during the quarter. Epoch Investment Partners Inc.'s holdings in Pfizer were worth $53,934,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Clarity Asset Management Inc. acquired a new stake in Pfizer in the fourth quarter worth $27,000. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the first quarter worth about $27,000. North Capital Inc. acquired a new stake in shares of Pfizer in the 1st quarter worth about $28,000. Finally, Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the 1st quarter worth about $28,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.97 on Wednesday. The stock has a market cap of $141.94 billion, a price-to-earnings ratio of 13.28, a PEG ratio of 0.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock's 50 day moving average price is $24.74 and its 200 day moving average price is $24.39.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company posted $0.60 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is presently 91.49%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of analyst reports. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Jefferies Financial Group lifted their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Finally, Redburn Atlantic reduced their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.